|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-3-10
|
|
pubmed:abstractText |
Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1534-4681
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1204-11
|
|
pubmed:meshHeading |
pubmed-meshheading:21076943-Antineoplastic Agents,
pubmed-meshheading:21076943-Blotting, Western,
pubmed-meshheading:21076943-Carcinoma, Hepatocellular,
pubmed-meshheading:21076943-Cisplatin,
pubmed-meshheading:21076943-DNA-Binding Proteins,
pubmed-meshheading:21076943-Drug Resistance, Neoplasm,
pubmed-meshheading:21076943-Endonucleases,
pubmed-meshheading:21076943-Female,
pubmed-meshheading:21076943-Humans,
pubmed-meshheading:21076943-Immunoenzyme Techniques,
pubmed-meshheading:21076943-Liver Neoplasms,
pubmed-meshheading:21076943-Male,
pubmed-meshheading:21076943-Middle Aged,
pubmed-meshheading:21076943-RNA, Small Interfering,
pubmed-meshheading:21076943-Survival Rate,
pubmed-meshheading:21076943-Treatment Outcome,
pubmed-meshheading:21076943-Tumor Cells, Cultured
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
